PD-1/PD-L1 inhibitors used alone or in combination as first-line therapy have demonstrated good long-term survival rates in various advanced cancers, including melanoma, lung cancer, gastric cancer, and others (25). The gene discussed is PDCD1; the disease is gastric cancer.